Table 1.
Clinical Characteristics and Therapy (n=270)
| Clinicopathological Factors | Mean (Range) | Frequency (%) | |
|---|---|---|---|
| Age (years) | 46.5 (24–76) | ||
| T-stage | pT1 | 59 | 21.85% |
| pT2 | 109 | 40.37% | |
| pT3 | 27 | 10.00% | |
| pT4 | 12 | 4.45% | |
| pTx | 63 | 23.33% | |
| N-stage | pN0 | 77 | 28.52% |
| pN1 | 51 | 18.89% | |
| pN2 | 56 | 20.74% | |
| pN3 | 72 | 26.67% | |
| pNx | 14 | 5.18% | |
| M-stage | pM0 | 257 | 95.19% |
| pM1 | 11 | 4.07% | |
| pMx | 2 | 0.74% | |
| Pathology | Intraductal carcinoma | 7 | 2.59% |
| Invasive Duct carcinoma | 218 | 80.74% | |
| Invasive lobular carcinoma | 18 | 6.67% | |
| Medullary carcinoma | 3 | 1.11% | |
| Rare types carcinoma | 24 | 8.89% | |
| Surgery | No | 12 | 4.44% |
| Modified radical operation | 250 | 92.59% | |
| Breast-conserving surgery | 6 | 2.22% | |
| Not sure | 2 | 0.74% | |
| Chemotherapy | No | 34 | 12.59% |
| Yes | 236 | 87.41% | |
| Radiotherapy | No | 160 | 59.25% |
| Yes | 110 | 40.74% | |
| Endocrine therapy | No | 131 | 54.13% |
| Tamoxifen | 91 | 33.70% | |
| Aromatase inhibitor ± GnRH | 34 | 12.59% | |
| Tamoxifen + GnRH | 5 | 1.85% | |
| Aromatase inhibitor +tamoxifen ± GnRH | 8 | 2.96% | |
| GnRH mono | 1 | 0.37% | |
| Trastuzumab therapy | No | 259 | 95.93% |
| Yes | 11 | 4.07% | |
| Metastasis | Lymph nodes, soft tissue, and bone | 136 | 50.37% |
| Viscus | 127 | 47.04% | |
| Brain | 7 | 2.59% | |
Abbreviations: T, primary tumor size; N, regional lymph node; M, distant metastasis, pT, pathological tumor; pN, pathological node; pM, pathological metastasis; GnRH, Gonadotropin-Releasing Hormone.